Welling­ton Part­ners tanks up with $237M for its next life sci fund — same strat­e­gy, but with more cash on hand

6 years ago
Financing

Ap­proval in sight, Per­cep­tive, Or­biMed dou­ble down on Foamix's an­tibi­ot­ic foam to the tune of $64M

6 years ago
Financing

Gates backs de­vel­op­ment work on a long-act­ing con­tra­cep­tive pill

6 years ago
R&D

Found­ing NewLink CEO Charles Link is out; Chi-Med lines up two more drug fil­ings

6 years ago
News Briefing

Eli Lil­ly ax­es an ear­ly-stage PD-L1/TIM-3 bis­pe­cif­ic pro­gram in lat­est pipeline cleanup

6 years ago
R&D

The patent play: Bio­gen gets a PhI­II boost for its bit-bet­ter take on the block­buster MS fran­chise drug Tec­fidera

6 years ago
R&D

Do you want to see what win­ning big in the R&D race looks like in the Big Phar­ma league?

6 years ago
Bioregnum
Opinion

FTC in­ves­ti­gates J&J con­tracts re­gard­ing the drug­mak­er's block­buster Rem­i­cade

6 years ago
Pharma
FDA+

Ve­rastem taps board di­rec­tor and Eli Lil­ly vet Bri­an Stug­lik to right the com­mer­cial boat

6 years ago
People

What is Pfiz­er go­ing to buy next? Al­bert Bourla out­lines his M&A strat­e­gy in the post-Up­john era

6 years ago
Deals
Pharma

No­var­tis’ Zol­gens­ma joins grow­ing list of med­i­cines to lose ac­cel­er­at­ed as­sess­ment sta­tus in EU

6 years ago
FDA+

Strapped for cash, Wood­ford's un­rav­el­ing con­tin­ues as list­ed fund con­sid­ers kick­ing him out as man­ag­er

6 years ago
People

Gen­fit's elafi­bra­nor wins or­phan sta­tus for pri­ma­ry bil­iary cholan­gi­tis; Cidara stock soars on pos­i­tive an­ti-fun­gal ...

6 years ago
News Briefing

Af­ter paint­ing a poor safe­ty pro­file, Pfiz­er and Eli Lil­ly are shoot­ing for a new pain drug OK any­way

6 years ago
R&D

As can­cer de­tec­tion com­pa­nies thrive, Ex­act Sci­ences looks to con­sol­i­date by spend­ing $2.8B to ac­quire peer Ge­nom­ic ...

6 years ago
Deals

Well­come Trust joins warn­ing for no-deal Brex­it, calls on Boris John­son to cast R&D vi­sion

6 years ago
People
Discovery

$20B-plus? Mer­ck keeps rack­ing up PhI­II suc­cess­es, scor­ing on triple neg­a­tive breast can­cer chal­lenge as an­a­lysts ...

6 years ago
R&D

Pfiz­er to com­bine its off-patent drug unit with My­lan

6 years ago
Deals

Thrashed by a 'sur­prise' ri­val, Sanofi writes off $2B on soured he­mo­phil­ia deal

6 years ago
Pharma

No­var­tis’ star block­buster flunks close­ly watched PhI­II — but they may file for key add-on OK any­way

6 years ago
R&D

Failed PhI­I­Is af­ter a re­jec­tion by the FDA spur Sanofi to dump its $1.7B deal with Lex­i­con on di­a­betes drug — ...

6 years ago
Deals
R&D

Ab­b­Vie scraps an an­ti-tau study, and that may fore­tell more big trou­ble for a be­lea­guered Bio­gen

6 years ago
R&D

EMA backs five med­i­cines; Sol­id Bio rais­es $60M in pri­vate place­ment

6 years ago
News Briefing

J&J touts their head-to-head win against Sanofi on MS, steer­ing an­oth­er S1P drug to the FDA

6 years ago
R&D
First page Previous page 927928929930931932933 Next page Last page
A service from the Financial Times